Celera had already issued a license or two in the past to Quest and interestingly enough when you go back through the history in 2002, Dr. Craig Venter was their leader an co-founder and we all know him now from his work with synthetic cells. The company also has a good size listing of US patents based on their discoveries and research. BD
From the Celera Website:
“Celera develops and commercializes diagnostic tests that identify disease risk and help physicians and patients manage disease development. Our Products business develops and manufactures molecular diagnostic products that are used to detect, characterize, monitor and select treatment for disease, while our Services business, Berkeley HeartLab, Inc. (BHL), offers many diagnostic tests to identify and characterize risk for cardiovascular disease and help physicians recommend treatment. Our 4myheart centers are staffed with medical professionals who use results from testing at BHL to work with patients, under their physician’s direction, to develop customized regimens for exercise, nutrition, stress management and therapy compliance. “
Quest Diagnostics said it will buy Celera Corp. for about $344 million to add genetic tests to its business.
The $8-a-share acquisition will add 1 percent to projected revenue growth this year, assuming the purchase is completed by the end of April, Madison-based Quest said today in a statement.
Celera, based in Alameda, Calif., was created to sequence the human genome and to find connections between genetic abnormalities and disease, the companies said.